These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23009178)

  • 1. DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer.
    Zhu J; Wang Y; Duan J; Bai H; Wang Z; Wei L; Zhao J; Zhuo M; Wang S; Yang L; An T; Wu M; Wang J
    J Exp Clin Cancer Res; 2012 Sep; 31(1):80. PubMed ID: 23009178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment.
    Que D; Xiao H; Zhao B; Zhang X; Wang Q; Xiao H; Wang G
    Cancer Biol Ther; 2016; 17(3):320-7. PubMed ID: 26785777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation.
    Griffiths EA; Gore SD; Hooker C; McDevitt MA; Karp JE; Smith BD; Mohammad HP; Ye Y; Herman JG; Carraway HE
    Leuk Lymphoma; 2010 Sep; 51(9):1711-9. PubMed ID: 20795789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
    Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer.
    Yang L; Tang C; Xu B; Wang W; Li J; Li X; Qin H; Gao H; He K; Song S; Liu X
    PLoS One; 2015; 10(6):e0128970. PubMed ID: 26047516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wnt5a promotes ewing sarcoma cell migration through upregulating CXCR4 expression.
    Jin Z; Zhao C; Han X; Han Y
    BMC Cancer; 2012 Oct; 12():480. PubMed ID: 23075330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic silencing of SFRP1 and SFRP5 by hepatitis B virus X protein enhances hepatoma cell tumorigenicity through Wnt signaling pathway.
    Xie Q; Chen L; Shan X; Shan X; Tang J; Zhou F; Chen Q; Quan H; Nie D; Zhang W; Huang AL; Tang N
    Int J Cancer; 2014 Aug; 135(3):635-46. PubMed ID: 24374650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation of Wnt antagonist genes: a useful prognostic marker for myelodysplastic syndrome.
    Wang H; Fan R; Wang XQ; Wu DP; Lin GW; Xu Y; Li WY
    Ann Hematol; 2013 Jan; 92(2):199-209. PubMed ID: 23093371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
    Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R
    Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy.
    Song J; Shi J; Dong D; Fang M; Zhong W; Wang K; Wu N; Huang Y; Liu Z; Cheng Y; Gan Y; Zhou Y; Zhou P; Chen B; Liang C; Liu Z; Li W; Tian J
    Clin Cancer Res; 2018 Aug; 24(15):3583-3592. PubMed ID: 29563137
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
    Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
    Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation analysis of SFRP genes family in cervical adenocarcinoma.
    Lin YW; Chung MT; Lai HC; De Yan M; Shih YL; Chang CC; Yu MH
    J Cancer Res Clin Oncol; 2009 Dec; 135(12):1665-74. PubMed ID: 19513747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
    Arriola E; García Gómez R; Diz P; Majem M; Martínez Aguillo M; Valdivia J; Paredes A; Sánchez-Torres JM; Peralta Muñoz S; Barneto I; Gutierrez V; Andrade Santiago JM; Aparisi F; Isla D; Ponce S; Vicente Baz D; Artal A; Amador M; Provencio M
    BMC Cancer; 2018 Jan; 18(1):106. PubMed ID: 29382302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer.
    Sun JM; Rampal S; Lee G; Lee J; Choi YL; Parasuraman B; Guallar E; Cho J; Shim YM
    Lung Cancer; 2013 May; 80(2):191-6. PubMed ID: 23384673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.
    Bai H; Wang Z; Chen K; Zhao J; Lee JJ; Wang S; Zhou Q; Zhuo M; Mao L; An T; Duan J; Yang L; Wu M; Liang Z; Wang Y; Kang X; Wang J
    J Clin Oncol; 2012 Sep; 30(25):3077-83. PubMed ID: 22826274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
    Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
    Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR.
    Wang F; Wang S; Wang Z; Duan J; An T; Zhao J; Bai H; Wang J;
    J Exp Clin Cancer Res; 2012 Aug; 31(1):65. PubMed ID: 22901364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.